Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

<p>Gene mutation analysis identified in 50 patients with PanNETs</p>

Na minha lista:

Detalhes bibliográficos
Autor principal:	Junfeng Xu (16437141) (author)
Outros Autores:	Zeng Ye (16437144) (author), Qifeng Zhuo (16437147) (author), Heli Gao (16437150) (author), Yi Qin (15400233) (author), Xin Lou (16437153) (author), Wuhu Zhang (16437156) (author), Fei Wang (16437159) (author), Yan Wang (16437162) (author), Desheng Jing (16437165) (author), Guixiong Fan (16437168) (author), Yue Zhang (16437171) (author), Xuemin Chen (16437174) (author), Jie Chen (16437177) (author), Xiaowu Xu (16437180) (author), Xianjun Yu (16437183) (author), Shunrong Ji (16437186) (author)
Publicado em:	2025
Assuntos:	Cancer Cancer Biology Clinical Research and Trials Endocrine-Related Cancers Oncogenes & Tumor Suppressors Precision Medicine Rare Cancers
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados

Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
Por: Junfeng Xu (16437141)
Publicado em: (2025)

Supplementary Data from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
Por: Dipika R. Mohan (15011204)
Publicado em: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Por: Clare Vesely (505402)
Publicado em: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Por: Clare Vesely (505402)
Publicado em: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Por: Clare Vesely (505402)
Publicado em: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Por: Clare Vesely (505402)
Publicado em: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Por: Clare Vesely (505402)
Publicado em: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Por: Clare Vesely (505402)
Publicado em: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
Por: Yemin Wang (17315078)
Publicado em: (2025)

Supplementary fig 1 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Por: Jiwei Bai (15051797)
Publicado em: (2025)

Supplementary fig 2 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Por: Jiwei Bai (15051797)
Publicado em: (2025)

Supplementary fig 3 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Por: Jiwei Bai (15051797)
Publicado em: (2025)

Supplementary fig 4 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Por: Jiwei Bai (15051797)
Publicado em: (2025)

Supplementary fig 5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Por: Jiwei Bai (15051797)
Publicado em: (2025)

Table S1-S5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Por: Jiwei Bai (15051797)
Publicado em: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Por: Dwight H. Owen (15034782)
Publicado em: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Por: Dwight H. Owen (15034782)
Publicado em: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Por: Dwight H. Owen (15034782)
Publicado em: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Por: Dwight H. Owen (15034782)
Publicado em: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Por: Dwight H. Owen (15034782)
Publicado em: (2025)

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Por: Evangeline R. Jackson (15558808)
Publicado em: (2025)

العمل بالأكثر والغالب عند الأصوليين: دراسة تطبيقية
Por: Al-mutiri, Aloush Khaled
Publicado em: (2022)

Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Por: Shiyi Yu (17079079)
Publicado em: (2025)

Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Por: Gwo Yaw Ho (14961416)
Publicado em: (2025)

Spreadsheet index of named bookbinders in the Sotheby's auction catalogues for the sales of the Major John Roland Abbey collection, sold between 1965 and 1989
Por: John Hodgson (22668215)
Publicado em: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Por: Alyssa C. Flint (16676029)
Publicado em: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Por: Alyssa C. Flint (16676029)
Publicado em: (2025)

Video 1_Imaging-driven diagnosis of retroperitoneal psoas major alveolar soft part sarcoma: a case report.mp4
Por: Shasha Wei (1555588)
Publicado em: (2025)

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Por: Laura Boucai (15054310)
Publicado em: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Por: Laura Boucai (15054310)
Publicado em: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Por: Laura Boucai (15054310)
Publicado em: (2025)

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Por: Laura Boucai (15054310)
Publicado em: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Por: Laura Boucai (15054310)
Publicado em: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Por: Laura Boucai (15054310)
Publicado em: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Por: Laura Boucai (15054310)
Publicado em: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Por: Laura Boucai (15054310)
Publicado em: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Por: Laura Boucai (15054310)
Publicado em: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Por: Laura Boucai (15054310)
Publicado em: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Por: John A. Ligon (15024477)
Publicado em: (2025)

Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx
Por: Xiaohu Jin (9618675)
Publicado em: (2025)

Cannot write session to /tmp/vufind_sessions/sess_8p7gbqjn3mlb9a5sqjdq2sfcru